Ceritinib

Target: This ligand targets anaplastic lymphoma kinase (ALK) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for anaplastic lymphoma kinase (ALK). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings anaplastic lymphoma kinase (ALK) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC Targeting of ALK: Ceritinib can be used as a binding ligand to recruit ALK-containing kinases in PROTAC designs, enabling ubiquitin-dependent degradation rather than inhibition alone. This approach supports studies of ALK signaling rewiring, resistance mechanisms, and degradation kinetics across ALK fusion variants and kinase domain mutants.

• Degradation of ALK Fusion Proteins: Incorporating ceritinib into PROTAC architectures can facilitate selective removal of ALK fusion proteins that drive oncogenic transcriptional programs. Researchers can evaluate whether degradation outperforms catalytic blockade by measuring target turnover, downstream pathway suppression, and phenotypic changes such as proliferation and survival in ALK-dependent cellular models.

• Comparative Studies Versus Inhibition: Ceritinib-based PROTACs enable direct comparison between degradation and conventional occupancy-based inhibition. By varying linker length and E3 ligase recruitment modules, experiments can map how changes in ternary complex formation influence degradation efficiency, duration of pathway shutdown, and emergence of compensatory signaling.

• Mechanistic Profiling of Ubiquitination: Using ceritinib as the targeting moiety supports mechanistic studies of ubiquitination and proteasome dependence in ALK-directed degradation. Researchers can quantify ubiquitin conjugates, assess proteasome sensitivity with chemical inhibitors, and determine whether degradation requires ALK kinase activity or specific conformational states.

• Resistance and Switch-Over Experiments: Ceritinib-derived PROTACs can be applied to probe how ALK mutations affect ligand engagement and degradation competence. Systematic testing across resistant alleles helps identify degradation “switch-over” conditions, guiding rational PROTAC optimization to restore turnover when inhibition-based strategies fail.

Ceritinib is a ALK kinase target ligand intended for use as the target-engaging component or reference ligand in PROTAC discovery workflows. Its known small-molecule recognition profile enables rational linker-vector evaluation and comparative degrader design. This molecule is described in detail below.

Structure: The structure of Ceritinib is characterized by primary or secondary amine/basic nitrogen centers; amide/urea/sulfonamide hydrogen-bonding motifs; halogenated aryl/heteroaryl ring system; heteroaromatic protein-recognition scaffold. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.